DNMT3A and chronic myelogenous leukemia, BCR-ABL1 positive: Overexpression or enhanced catalytic activity of DNMT1, DNMT3a, and DNMT3b has been observed in multiple cancers, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), glioma, and breast, gastric, colorectal, hepatocellular, pancreatic, prostate, and lung cancers [20].